Seattle Genetics Initiates Phase II Clinical Trials With SGN-15; Two Trials Commencing for Patients With Breast or Colorectal Cancers.Health/Medical Writers BOTHELL, Wash.--(BW HealthWire)--Oct. 31, 2000 Seattle Genetics, Inc. announced the initiation of phase II clinical testing with one of its lead monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing drug conjugates, SGN-15. "We are very excited to progress into phase II with this promising anticancer agent," stated Dr. Amy Sing, Senior Director of Medical Affairs at Seattle Genetics. Two phase II efficacy studies are being conducted, one for patients with advanced breast carcinoma and a second for patients with advanced colorectal carcinoma. Both studies will be evaluating SGN-15 in combination with the chemotherapeutic drug Taxotere(R), a leading cancer treatment from Aventis Pharmaceuticals. Seattle Genetics recently completed a phase I clinical testing of the SGN-15 and Taxotere(R) combination in patients with breast or colorectal carcinoma. The combination regimen was safely administered to 16 patients in the phase I study that identified the best dose of SGN-15 to be used in combination with Taxotere(R) in phase II. Aventis Pharmaceuticals is co-funding the clinical costs of both the phase I and phase II trials and is providing the Taxotere(R) drug. The phase II studies have opened at the University of Alabama The University of Alabama (also known as Alabama, UA or colloquially as 'Bama) is a public coeducational university located in Tuscaloosa, Alabama, USA. Founded in 1831, UA is the flagship campus of the University of Alabama System. , Birmingham Comprehensive Cancer Center, Birmingham, AL; Georgia Cancer Specialists in Atlanta, GA; and the Lombardi Cancer Institute at Georgetown University Medical Center Georgetown University Medical Center (GUMC) is the medical campus at Georgetown University. It is co-located with Georgetown University Hospital on the University's main campus in Washington, DC. in Washington, D.C.; with other sites to be added later. "We are pleased to be testing the SGN-15 and Taxotere(R) combination regimen at these premier cancer centers," stated Dr. Clay B. Siegall, President and Chief Scientific Officer of Seattle Genetics. "We are also very pleased to have the support of Aventis Pharmaceuticals, one of the world's largest pharmaceutical companies." Seattle Genetics, Inc. is a privately held biotechnology company focused on developing novel therapeutics to enhance the survival of cancer patients. The Company's research and development initiatives use monoclonal antibody-based therapeutics encompassing four technology platforms: antibody-drug conjugates (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ), single-chain immunotoxins (SCIT SCIT Symbiosis Centre for Information Technology (Pune, India) SCIT Storm Cell Identification and Tracking SCIT Saginaw Chippewa Indian Tribe (Mount Pleasant, Michigan) SCIT State Corporate Income Tax ), monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). (mAbs), and antibody-directed enzyme prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. therapy (ADEPT). Seattle Genetics has two drugs currently in four clinical trials, including SGN-10, a SCIT being tested in two phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I in carcinoma patients, two in late-stage development and several lead agents undergoing preclinical testing. One of the late-stage development drug candidates targeted to CD40 is being developed for the treatment of certain hematologic malignancies through an alliance with Genentech, Inc. For more information about Seattle Genetics, please visit the Company's web site at www.seattlegenetics.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion